Market Overview

Mylan Pharma Wins Final FDA Approval for ANDA for Phenytoin Chewable Tablets, 50 mg

Related MYL
Benzinga's M&A Chatter for Monday September 26, 2016
Andrew Left On Valeant: 'Eliminating Price Gouging' Likely Sole Agreement Between Presidential Nominees
2 Takeaways From The Mylan Congressional EpiPen Hearing (Seeking Alpha)
Related PFE
The Market In 5 Minutes: Oil, Debates And Epidiolex
A Peek Into The Markets: U.S. Stock Futures Signal Lower Start On Wall Street
Presidential Debate a Factor for the Market This Week (GuruFocus)

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Phenytoin Chewable Tablets USP, 50 mg. This product is the generic version of Pfizer's Dilantin® Chewable Tablets, which are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. Phenytoin serum level determinations may be necessary for optimal dosage adjustments.

Posted-In: News FDA


Related Articles (MYL + PFE)

View Comments and Join the Discussion!